Novocure's cancer therapy fails to meet main goal in late-stage trial (updated)

NovoCure

28/08/2023 12:27

(Adds details in paragraphs 2 and 3)
       Aug 28 (Reuters) - Novocure  NVCR.O  said on Monday its
therapy failed in a late-stage trial to meet the main goal of
improving survival rates in patients with a type of ovarian
cancer. 
  Novocure's therapy, which is used with certain chemotherapies
and immunotherapies, creates electric fields that exert physical
forces to kill cancer cells.
        The combination therapy showed an overall survival rate
of 12.2 months compared to 11.9 months in patients who were
treated only with paclitaxel - the chemotherapy it was combined
with.
  
        
  
        
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Nivedita
Bhattacharjee)
 ((Sriparna.Roy@thomsonreuters.com;))